Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZiCAR-002
- Development stage
- Unknown
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ZiCAR-002 is an investigational cell therapy being studied for the treatment of hepatocellular carcinoma. The primary objectives in clinical trials are to determine its safety, tolerability, and dose-limiting toxicity in patients with this cancer. While detailed mechanistic information is not provided in the available sources, the name "ZiCAR" suggests it may be a chimeric antigen receptor (CAR) T-cell therapy or a related engineered cell therapy modality[1].
- Brand names
- ZiCAR-002ZiCAR002ZiCAR 002
- Other names
- ZiCAR-002ZiCAR002ZiCAR 002
Beyond the preview
Go deeper on ZiCAR-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZiCAR-002.